Navigation Links
DrugRisks News Update: Bayer Loses Yaz Patent as Blood Clot Settlements Continue
Date:4/26/2013

Chicago, IL (PRWEB) April 26, 2013

The birth control safety advocates at DrugRisks.com have added new information to the site for women using the contraceptives Yaz or Yasmin. A court recently ordered that Bayer no longer holds a patent on the drugs as the company continues to settle claims from patients alleging blood clot injuries**.

DrugRisks was created to give patients taking popular prescription drugs like Yaz and Yasmin the latest warnings, recalls, studies and legal news. With access to clear information, patients can discuss side effect concerns with their doctor and decide if they need legal advice.

The British Medical Journal and FDA have cautioned that birth control pills containing drospirenone, like Yaz and Yasmin, can increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%*.

With a growing number of patients filing a Yaz lawsuit alleging blood clot injuries, cases were consolidated to a special federal Multi-District Litigation court in Illinois (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).

Now, DrugRisks has added information showing the U.S. Circuit Court of Appeals for Washington last week ruled Bayer’s patent on Yaz, which was set to expire in 2014, is no longer valid**. This will allows competitors Actavis, Sandoz and Lupin to continue selling their generic versions of the drug**.

Bayer’s latest financial reports show the company has spent nearly $1 billion to settle around 4,800 claims alleging Yaz blood clots, and will continue to evaluate new claims for settlement on a case-by-case basis***.

Lawyers are still helping those affected file a claim. Anyone who suffered a blood clot, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin is urged to contact the DrugRisks Center or speak with a lawyer about their legal options.

Due to the specialized nature of federal MDL drug injury cases, DrugRisks cautions that patients should seek a lawyer with experience in this litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.

Visit http://www.DrugRisks.com today for more information on the research, Yaz side effects and litigation news related to Yaz or Yasmin, or to speak with a lawyer.

*British Medical Journal, October 25, 2011, University of Copenhagen; FDA, October 27, 2011, "Combined Hormonal Contraceptives and the Risk of Cardiovascular Disease Endpoints"
**businessweek.com/news/2013-04-16/bayer-patent-on-yaz-birth-control-pill-ruled-invalid
***Bayer 2012 Annual Report, Consolidated Financial Statement, Legal Notes, February 28, 2013

Read the full story at http://www.prweb.com/releases/yaz-side-effects/2013-settlement-news/prweb10662368.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisks Adds Update From Court Ordering Mediation of Stryker Hip Lawsuits
2. DrugRisks Update: Federal Court Schedules First Mirena Lawsuit Hearing
3. DrugRisks Legal Update: Jury to Decide Actos Cancer Trial This Week
4. DrugRisks Update: Doctor Testifies Actos Main Cause of Bladder Cancer in Trial
5. DrugRisks Adds Study Showing Pradaxa Viral Infection Risk
6. DrugRisks Stryker Recall Update: Company Warns Investors as Patients Alleging Injury Ask to Send Lawsuits to Federal Court
7. DrugRisks Center NuvaRing Lawsuit News: Drug Maker May Have Concealed Risks
8. DrugRisks Adds New Pradaxa Study Alert As Lawsuits Increase
9. DrugRisks Adds Update from First Actos Trial of Patient Alleging Bladder Cancer
10. Transvaginal Mesh Complications Lawsuits Update: Resource4thePeople Reports Some CasesDismissed from Consolidated Litigation
11. DrugRisk Update: Court Asks for Pradaxa Lawsuit Test Cases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that has ... presence to an educational purpose as the host of the “Informed” series. The program ... a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer is ...
(Date:4/27/2017)... ... , ... Healthcare companies are trying to meet talent shortages and find new ... resume. , “If you’re a healthcare executive open to new opportunities this year you’re ... ready as you are for a new job search. I’ve heard from countless job ...
(Date:4/27/2017)... ... , ... Goodcents Deli Fresh Subs announced a franchise expansion agreement today including ... , The first new location will open at the corner of 27th and Randolph ... Lights Drive this fall. And the third location is in the process of being ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... outcomes, today released the podcast, “Make Plans for MACRA,” highlighting the ... into the physician's office and how physicians and other clinicians are reimbursed for ...
(Date:4/26/2017)... ... 2017 , ... Elisabete Miranda, president and CEO of ... magazine as one of its 2017 Enterprising Women of the Year, a prestigious ... that they have fast-growth businesses, mentor or actively support other women and girls ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will participate ... the Sheraton Hotel in Toronto, Ontario . ... is scheduled to present on Tuesday, May 2 at 10:00 am. ... the Board, Tony Holler will also attend the event. ... For more details about the ...
Breaking Medicine Technology: